EirGenix, Inc. (TWSE: 6589), a leading Taiwanese biopharmaceutical contract development and manufacturing organization (CDMO), held a grand inauguration ceremony on September 16 for its new microbial facility in Zhubei. The new facility primarily enhances production capacity for microbial protein expression and plasmid DNA (pDNA) and will boost the company’s existing microbial fermentation capacity ninefold. During the ceremony, the company also…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.